Upstream Bio Inc expected to post a loss of 76 cents a share - Earnings Preview

Upstream Bio

31/07/2026 14:52

Upstream Bio Inc UPB.OQ UPB.O is expected to  show a fall in quarterly revenue when it reports  results on August 4 (estimated) for the period ending June 30 2026
The Waltham Massachusetts-based  company is expected to report a 54.0% decrease in revenue to $430.71 thousand from $937 thousand a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Upstream Bio Inc is for a loss of 76 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Upstream Bio Inc is $42.50, about 546.9% above its last closing price of $6.57
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.78
-0.77
-0.75
Beat
3
Dec. 31 2026
-0.72
-0.70
-0.78
Missed
-12.3
Sep. 30 2025
-0.78
-0.78
-0.63
Beat
19.4​
Jun. 30 2025
-0.61
-0.61
-0.74
Missed
-20.8
​​Mar. 31 2025
-0.49
-0.48
-0.51
Missed
-5.2
Dec. 31 2024
-0.56
-1.59
Missed
-183.9​
Sep. 30 2024
-3.68
-3.68
-6.96
Missed
-89.1
This summary was machine generated July 31 at 13:52 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)